azacitidine has been researched along with Brittle Bone Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, T; Jing, Y; Li, G; Li, J; Liu, Y; Lv, Z; Shao, C; Wang, Z; Zhao, Y | 1 |
1 other study(ies) available for azacitidine and Brittle Bone Disease
| Article | Year |
|---|---|
DNA methyltransferases inhibitor azacitidine improves the skeletal phenotype of mild osteogenesis imperfecta by reversing the impaired osteogenesis and excessive osteoclastogenesis.
Topics: Animals; Azacitidine; Collagen; Disease Models, Animal; DNA; Enzyme Inhibitors; Methyltransferases; Mice; Osteogenesis; Osteogenesis Imperfecta; Phenotype | 2023 |